Skip to content

Welcome to Discover Pharma! Today is : November 12, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Drug Discovery & Development

  • Advanced Therapies,Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    Complement Therapeutics receives FDA IND clearance for CTx001 to enter Opti-GAIN trial in geographic atrophy

    Complement Therapeutics GmbH (CTx) has received clearance from the FDA [...]

    May 5, 2026
  • Biotech & Pharma Business,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    Atrial fibrillation market forecast to decline to $10.5bn by 2032 amid NOAC sales erosion

    The atrial fibrillation (AF) market across the eight major markets [...]

    May 5, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    Skye Bioscience Phase 2a data show added weight loss with nimacimab–semaglutide combination

    Skye Bioscience has reported topline results from its Phase 2a [...]

    May 5, 2026
  • Biotech & Pharma Business,Drug Discovery & Development,Genomics and sequencing,Therapeutic Areas

    Chiesi and Arbor partner on rare disease gene editing programmes targeting PH1 and other liver disorders

    Chiesi Group has entered into an exclusive global partnership with [...]

    May 5, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    CytoAgents receives fourth NIH grant to advance research on cytokine release syndrome in CAR T-cell therapy

    CytoAgents, a clinical-stage biotechnology company developing an oral small-molecule immune [...]

    May 5, 2026
  • Central Nervous System,Clinical & Regulatory,Drug Discovery & Development,Medical devices,Pharmaceuticals and therapeutics

    Owlstone Medical awarded up to $49.1 million from ARPA-H to develop at-home multi-cancer early detection tests

    Owlstone Medical has received an award of up to $49.1 [...]

    May 5, 2026
  • Central Nervous System,Clinical & Regulatory,Drug Discovery & Development

    Alto Neuroscience receives FDA Fast Track designation for ALTO-101 to treat cognitive impairment in schizophrenia

    Alto Neuroscience has received FDA Fast Track designation for its [...]

    May 5, 2026
  • Biotech & Pharma Business,Digital & Data,Drug Discovery & Development

    Sapio Sciences appoints Rich Roda as chief financial officer

    Sapio Sciences has appointed Rich Roda as chief financial officer, [...]

    May 5, 2026
  • Biotech & Pharma Business,Drug Discovery & Development,Therapeutic Areas

    Myricx Bio appoints Boston-based Mohit Rawat as CEO and expands team in US and UK

    Myricx Bio has appointed Boston-based Mohit Rawat as chief executive [...]

    May 5, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Digital & Data,Drug Discovery & Development

    OptymEdge appoints senior director to lead global roll-out of ACUVERA platform

    OptymEdge has appointed Amy Del Medico as senior director of [...]

    May 5, 2026
Previous454647Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • FDA grants Priority Review to Belite Bio’s tinlarebant for Stargardt disease
    Categories: Clinical & Regulatory, Drug Delivery & Formulation, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • Skylark Bio doses first patient in Phase 1/2 trial for GJB2-related deafness
    Categories: Advanced Therapies, Clinical & Regulatory, Genomics and sequencing, Research & Development, Therapeutic Areas
  • CellProthera and Alfresa sign MOU for ProtheraCytes Phase 3 trial in Japan
    Categories: Advanced Therapies, Biotech & Pharma Business, Clinical & Regulatory, Pharmaceuticals and therapeutics, Research & Development
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top